Ultragenyx Pharmaceutical | RARE - Loan Capital


Ultragenyx Pharmaceutical reported $1.13B in Loan Capital for its fiscal quarter ending in March of 2026.





Loan Capital Change Date
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Alnylam Pharmaceuticals USD 2.47B 6.56M Jun/2026
BioCryst Pharmaceuticals USD 395.4M 203K Jun/2026
BioMarin Pharmaceutical USD 3.53B 2.1B Jun/2026
Immunic USD 0 0 Jun/2024
Insmed USD 543.51M 1.3M Jun/2026
Ionis Pharmaceuticals USD 1.91B 6.62M Jun/2026
Karyopharm Therapeutics USD 264.49M 13.73M Mar/2026
Kyowa Hakko Kirin JPY 24.12B 5.27B Dec/2024
MacroGenics USD 68.71M 1.29M Mar/2026
Moderna USD 597M 6M Jun/2026
Neurocrine Biosciences USD 169.5M 500K Mar/2023
PTC Therapeutics USD 535.52M 248.58M Jun/2026
Puma Biotechnology USD 10.87M 222K Jun/2025
Regeneron Pharmaceuticals USD 1.99B 400K Jun/2026
Sarepta Therapeutics USD 847.62M 9.46M Jun/2026
Ultragenyx Pharmaceutical USD 1.13B 19M Mar/2026
Vertex Pharmaceuticals USD 106.7M 4.7M Dec/2025